NDA 216386 · Pfizer
Zavzpret
Zavegepant Hydrochloride · Nasal
NovelCDER novel approval, Mar 9, 2023: To treat migraine
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 9, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
6 Phase 3, 3 recruiting
FAERS reports
892
83 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 26, 2025.
ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ( 1 )
Mechanism: Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZAVZPRET · ZAVEGEPANT HYDROCHLORIDE EQ 10MG BASE/SPRAY · SPRAY, METERED, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zavegepant" as an intervention, any sponsor and status, largest first.
- Acute Treatment Trial in Adult Subjects With MigrainesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03872453 · 2,154 participants · Start Mar 25, 2019 · Primary completion Oct 31, 2019
Drug: Zavegepant; Zavegepant matching placebo · For: Migraine
Sites: Mobile, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 82 sites in all
- Randomized Trial in Adult Participants With Acute MigrainesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04571060 · 1,978 participants · Start Oct 27, 2020 · Primary completion Oct 10, 2021
Drug: Zavegepant; Placebo · For: Migraine
Sites: Huntsville, Alabama; Mobile, Alabama; Chandler, Arizona · 94 sites in all
- A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine PreventionPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT04804033 · 1,753 participants · Start Mar 26, 2021 · Primary completion Mar 21, 2024
Drug: BHV-3500 (zavegepant); Placebo · For: Migraine
Sites: Phoenix, Arizona; Tucson, Arizona; Canoga Park, California · 116 sites in all
- A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05989048 · 1,414 participants · Start Nov 29, 2023 · Primary completion May 30, 2025
Drug: Zavegepant; Placebo · For: Migraine
Sites: Hefei, China; Beijing, China; Chongqing, China · 61 sites in all
- Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of MigrainePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04408794 · 974 participants · Start Jun 29, 2020 · Primary completion Dec 9, 2021
Drug: Zavegepant (BHV-3500) · For: Acute Migraine
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 67 sites in all
- A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of MigraineNot yet recruiting
American Center for Psychiatry and NeurologyAcademic, hospital or other
NCT07861412 · 250 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 30, 2027
Drug: intranasal zavegepant · For: Migraine
Mayo ClinicAcademic, hospital or other
NCT06401642 · 200 participants (planned) · Start Mar 22, 2024 · Primary completion Mar 2027
Drug: Zavegepant · For: Migraine
Sites: Phoenix, Arizona
University of South FloridaAcademic, hospital or other
NCT07667621 · 100 participants (planned) · Start Sep 15, 2026 · Primary completion Jul 2027
Drug: Rimegepant; Zavegepant · For: Migraine; Migraine Disease; Migraine in Adults and 4 more
Sites: Tampa, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dysgeusia259
- drug ineffective147
- nasal discomfort85
- nausea81
- throat irritation75
- vomiting71
- migraine45
- therapeutic product effect incomplete44
- headache38
- off label use36
- taste disorder36
- burning sensation31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 236 |
| 2024 | 266 |
| 2025 | 248 |
| 2026 | 142 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zavzpret (Zavegepant HCl)
2024 spending
$8.9M
Beneficiaries
2,783
7,727 claims
Per beneficiary
$3,209
$177.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $2,306,719 |
| 2024 | $8,929,258 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Croop R, Madonia J, Stock DA, et al. · Headache 2022 · Randomized Controlled Trial, Clinical Trial, Phase II
- Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
Lipton RB, Croop R, Stock DA, et al. · Lancet Neurol 2023 · Randomized Controlled Trial, Multicenter Study
- Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
Mullin K, Croop R, Mosher L, et al. · Cephalalgia 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.
Bhardwaj R, Donohue MK, Madonia J, et al. · Clin Transl Sci 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial.
Powell L, O'Sullivan F, Jayasinghe P, et al. · J Headache Pain 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Suresh V, Bardhan M, Dave T, et al. · Clin Neuropharmacol 2024 · Systematic Review, Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.